Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group

Moore, Caroline M.; Kasivisvanathan, Veeru; Eggener, Scott E.; Emberton, Mark; Fütterer, Jurgen J.; Gill, Inderbir S.; Grubb, Robert L.; Hadaschik, Boris; Klotz, Laurence; Margolis, Daniel; Marks, Leonard S.; Melamed, Jonathan; Oto, Aytekin; Palmer, Suzanne; Pinto, Peter A.; Puech, Philippe; Punwani, Shonit; Rosenkrantz, Andrew B.; Schoots, Ivo G.; Simon, Richard; Taneja, Samir S.; Türkbey, Barış; Ukimura, Osamu; Meulen, Jan van der; Villers, Arnauld; Watanabe, Yuji

doi:10.1016/j.eururo.2013.03.030

Cited by 395 publications

(265 citation statements)

References 15 publications

Supporting

Mentioning

254

Contrasting

Unclassified

Order By: Relevance

“…2) сокращение числа случаев неоправданных би-опсий и лечения за счет повышения доверия в выяв-лении доброкачественных изменений и латентных форм опухолей, которые не являются критическими факторами в определении продолжительности жизни мужчин [4,5].…”

Section: диагностика и лечение опухолей мочеполовой системы рак предunclassified

“…Следует заметить, что в последнее время отмеча-ется тенденция повышения компетенции мпМРТ, в связи с чем накапливается положительный опыт ис-пользования МРТ-навигации для биопсий ПЖ [4,5,16]. В соответствии с опубликованным руководством PI-RADSv2 следует помнить, что целесообразность проведения таргетной биопсии ПЖ может рассматри-ваться при категории не менее чем PI-RADS 3.…”

Section: шкалаunclassified

See 1 more Smart Citation

A system of a unified approach to interpreting prostate magnetic resonance imaging according to the PI-RADSv2 guidelines

Мищенко¹,

Рубцова²,

Алексеев³

et al. 2016

Cancer Urology

View full text Add to dashboard Cite

show abstract

Section: диагностика и лечение опухолей мочеполовой системы рак предunclassified

Section: шкалаunclassified

A system of a unified approach to interpreting prostate magnetic resonance imaging according to the PI-RADSv2 guidelines

Мищенко¹,

Рубцова²,

Алексеев³

et al. 2016

Cancer Urology

View full text Add to dashboard Cite

show abstract

“…Based on our hypothesis 2 sub-investigation were proposed; sub-investigation 1 consists of superiority study comparing the TDR of MRF and 'cognitive' TRUS biopsy; and sub-investigation 2 consists of a non-inferiority study comparing the TDR of MRF and MRGB. The study design and protocol drafting for the FUTURE trial was performed in adherence to the CONSORT, SPIRIT and START recommendations for reporting on interventional trials [16,43,44]. …”

Section: Methodsmentioning

confidence: 99%

“…Development of multiparametric MRI (mpMRI) techniques has increased the detection of significant cancers and the sensitivity for the determination of its aggression [15][16][17][18][19][20][21][22]. Clinical guidelines advise performing an mpMRI when the clinical suspicion on prostate cancer persists despite prior negative TRUS biopsy results to investigate the possibility of ventrally located lesions [3,4].…”

Section: Introductionmentioning

confidence: 99%

Fusion Target Biopsy of the Prostate Using Real-Time Ultrasound and MR Images. A Multicenter RCT on Target Biopsy Techniques in the Diagnosis of Prostate Cancer

Wegelin¹,

Melick²

2015

J Clin Trials

View full text Add to dashboard Cite

Background: The current standard technique for prostate cancer detection is trans-rectal ultrasound (TRUS) guided biopsy, and is renowned for its low sensitivity. Developments of multiparametric MRI techniques have increased the detection of significant prostate cancer. Currently there are three techniques utilizing MRI for targeted biopsy: MRI-TRUS fusion, 'cognitive' TRUS, and in-bore MRI guided biopsy. There is no consensus which should be preferred. The current study aims to compare prostate cancer detection rates of three target biopsy procedures.

show abstract

“…23 Biopsy results were compared using the highest GS obtained by each technique. Clinically significant cancer was assessed by the presence of any Gleason pattern 4 or greater in the biopsy (GS 7-10) and/or lesion volume more than 0.5 ml.…”

Section: Data Analysis and Statisticsmentioning

confidence: 99%

Transrectal ultrasound-guided biopsy for prostate cancer detection: Systematic and/or magnetic-resonance imaging-targeted

Bladou

Fogaing

Levental

et al. 2017

CUAJ

View full text Add to dashboard Cite

Introduction: Magnetic resonance imaging (MRI) is being more widely used in the detection of prostate cancer (PCa), particularly after an initial negative biopsy. In this study, we compared 12-core systematic biopsy (SYS), MRI-targeted biopsy (TAR), and the association of systematic and MRI-targeted (SYS+TAR) prostate biopsy in patients with previous biopsy and those who were biopsy-naive to evaluate the differences in terms of cancer detection and clinically significant cancer detection between the three modalities. Methods: Overall, 203 consecutive patients with suspicion of PCa were analyzed; 48.2% were biopsy-naive and 51.7% had at least one previous negative prostate biopsy. The median age was 66 years, median prostate-specific antigen (PSA) level was 7.9 ng/mL and median prostate volume was 46 mL. 38.9% had SYS, 19.2% TAR only, and 41.8% had SYS+TAR biopsy. Results: Overall, the PCa detection (PCaDR) was 63%. The SYS+TAR biopsy detected significantly more cancer than SYS and TAR only biopsies (72.9% vs. 56.9% and 53.8% respectively; p=0.03). Detection rate of clinically significant cancer (csPCaDR) was 50.7% overall; 65.8% in the SYS+TAR biopsy vs. 39.2% in the SYS and 48.7% in the TAR groups (p=0.002). In the biopsy-naive group, PCaDR and csPCaDR were significantly higher in the SYS+TAR group than in the SYS and TAR groups (p=0.01). In the repeat biopsy group, PCaDR and csPCaDR were equivalent in the TAR and SYS+TAR groups and higher than in the SYS group (p=0.001). Conclusions: TAR biopsy, when added to SYS biopsy, was associated with a higher detection rate of csPCa in biopsy-naive patients when compared to TAR and SYS only biopsies. In patients after previous negative biopsy, detection rates of csPCa were equivalent for SYS+TAR and TAR only biopsies, but higher than SYS.

show abstract

Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group

Cited by 395 publications

References 15 publications

A system of a unified approach to interpreting prostate magnetic resonance imaging according to the PI-RADSv2 guidelines

A system of a unified approach to interpreting prostate magnetic resonance imaging according to the PI-RADSv2 guidelines

Fusion Target Biopsy of the Prostate Using Real-Time Ultrasound and MR Images. A Multicenter RCT on Target Biopsy Techniques in the Diagnosis of Prostate Cancer

Transrectal ultrasound-guided biopsy for prostate cancer detection: Systematic and/or magnetic-resonance imaging-targeted

Contact Info

Product

Resources

About